Boundless Bio, Inc.(BOLD) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 Research and Development Highlights and Upcoming Milestones BBI-940 novel Kinesin program targeting ecDNA segregation and inheritance $118 million in cash supports operations into first half of ...